According to the information released by the World Health Organization (WHO) in 2008, lung cancer ranks first in the world in terms of both the number of annual incidence (1.6 million) and the number of deaths (1.4 million), and the famous British oncologist R. Peto predicts that if China does not control smoking and air pollution in time, the annual number of lung cancer incidence in China will If China does not control smoking and air pollution in time, the annual number of lung cancer cases in China will exceed 1 million by 2025, making it the world’s largest lung cancer country. At present, the main treatment options for lung cancer at home and abroad are chemotherapy, radiotherapy, surgery and targeted therapy, but the effect is often limited, so there is an urgent need for human beings to make a breakthrough in the research and diagnosis of lung cancer. The respiratory team led by Prof. Chang-Hui Wang at Shanghai Tenth People’s Hospital has made significant achievements in the field of adenylate cyclase – associated protein 1 (cap1) and non-small cell lung cancer (nsclc) metastasis research, which cap1 was found to promote lung cancer cell proliferation and metastasis through the limk1/cofilin signaling pathway. The study will be presented at the upcoming annual meeting of the European Respiratory Society (ERS 2015) by Prof. Wang Changhui’s team from the Department of Respiratory Medicine, Tenth People’s Hospital, Tongji University, Shanghai. The study is divided into 3 parts. First, the researchers assessed CAP1 levels in 82 lung cancer patients by quantitative polymerase chain reaction (RT-PCR), protein blot analysis and immunohistochemistry (IHC). Second, the researchers assessed and followed up (4 years) CAP1 levels in 50 lung cancer patients with brain metastases (BM group) and 70 lung cancer patients without brain metastases (non-BM group). Finally, the researchers assessed CAP1 expression in normal lung cells by protein blot analysis and RT-PCR. In addition, the study also evaluated the expression of Si-CAP1, empty vector plasmid and CAP1 in lung cancer cell lines A549, 95-C and 95-D by cell proliferation assay MTT, cell scratch assay, Transwll cell invasion assay, protein blot analysis and IHC analysis. This study revealed that lung cancer cells, especially those with combined BM, had high CAP1 expression. In vitro and ex vivo experiments revealed that CAP1 could promote the proliferation and metastasis of lung cancer cells through the limk1/cofilin signaling pathway. The above results suggest that CAP1 can promote the proliferation and metastasis of lung cancer cells through the limk1/cofilin signaling pathway, and CAP1 is closely related to the metastasis of NSCLC, especially in patients with combined BM.